Alkermes shares plunge after drug misses trial goals
January 21, 2016 at 08:42 AM EST
ALKS 5461, a drug that aims to treat clinical depression, failed to meet goals for two of three clinical trials, with a third trial ongoing.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.